

PRESS RELEASE

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 13, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the half-year report of the liquidity contract with *Crédit Industriel et Commercial*.

Under the liquidity contract GENFIT has with *Crédit Industriel et Commercial*, the following resources appeared on the liquidity account as of December 31, 2025:

- 16,177 shares
- €1 109 238.29

During the second half of 2025, total trading was:

- On the buy side: 1,330,219 shares for a total amount of €4,996,375.72
- On the sell side: 1,515,142 shares for a total amount of €5,707,129.34

During this same period, the number of trades were:

- On the buy side: 2,585
- On the sell side: 2,576

As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

- 27,911 shares
- €769,849.43

END

ABOUT GENFIT

GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades.

PRESS RELEASE

Today, GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow.

GENFIT's expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for the treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.¹

Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis).

GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT). In 2021, Ipsen became one of GENFIT's largest shareholders, acquiring an 8% stake in the Company's capital. www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995, in relation to GENFIT's research and development programs. The use of certain words, such as "believe", "potential", "expect", "target", "may", "will", "should", "could", "if" and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company's management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to non-clinical and pre-clinical programs, reproducibility of preclinical results, the translation of animal model data to human biology, in

¹ Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo®.

PRESS RELEASE

relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company's public filings with the AMF, including those listed in Chapter 2 "Risk Factors and Internal Control" of the Company's 2024 Universal Registration Document filed on April 29, 2025 (no. 25-0331) with the Autorité des marchés financiers ("AMF"), which is available on GENFIT's website (www.genfit.fr) and the AMF's website (bdf.amf-france.org), and those discussed in the public documents and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's 2024 Annual Report on Form 20-F filed with the SEC on April 29, 2025 and subsequent filings and reports filed with the AMF or SEC or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACTS

GENFIT | Investors

Tel: +33 3 2016 4000 | investors@genfit.com

GENFIT | Media

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

PRESS RELEASE

APPENDIX H2 2025

Date	Buy side			Sell side		
	Number of executions	Number of shares	Traded amounts in EUR	Number of executions	Number of shares	Traded amounts in EUR
TOTAL	2 585	1 330 219	4 996 375,72	2 576	1 515 142	5 707 129,34
01/07/2025	22	6800	22 297,68	18	8816	29 006,23
02/07/2025	15	6651	22 021,33	21	7936	26 417,75
03/07/2025	51	26399	88 188,24	26	19573	65 627,68
04/07/2025	21	13081	43 260,83	18	18653	61 921,62
07/07/2025	33	21136	69 530,47	11	6423	21 251,20
08/07/2025	13	6321	20 545,97	14	8705	28 339,74
09/07/2025	13	4500	14 704,02	20	11751	38 451,62
10/07/2025	30	11334	37 338,73	32	21779	71 993,97
11/07/2025	36	11068	36 264,08	15	4720	15 514,22
14/07/2025	29	10674	34 589,20	36	11101	36 073,81
15/07/2025	25	12701	43 420,27	51	32982	111 612,08
16/07/2025	14	11809	39 684,50	31	16075	54 363,08
17/07/2025	16	6364	21 343,33	17	8293	27 858,84
18/07/2025	27	12030	40 934,72	37	14567	49 740,33
21/07/2025	42	20051	67 104,48	17	8748	29 340,18
22/07/2025	26	14306	47 190,20	16	8756	28 927,99
23/07/2025	33	15701	53 628,34	48	33532	113 250,31
24/07/2025	45	24001	83 872,45	55	32930	115 532,27
25/07/2025	7	9727	34 197,02	13	17601	62 197,01

PRESS RELEASE

28/07/2025	12	8202	29 743,81	27	14015	50 857,77
29/07/2025	24	14616	53 176,52	20	11594	42 866,03
30/07/2025	14	11501	40 588,64	17	8123	28 835,43
31/07/2025	19	9301	32 595,54	15	10788	38 101,38
01/08/2025	22	22001	74 968,41	38	24929	84 488,62
04/08/2025	8	2516	8 464,91	10	8313	28 238,60
05/08/2025	1	1	3,37	22	13189	44 953,65
06/08/2025	20	10002	33 589,52	2	2	6,92
07/08/2025	5	1501	4 956,30	23	11501	38 540,54
08/08/2025	10	3001	10 009,33	11	4001	13 463,32
11/08/2025	17	5001	16 697,34	8	4001	13 451,36
12/08/2025	9	4678	15 706,85	10	4678	15 774,36
13/08/2025	1	1	3,36	27	19501	67 503,30
14/08/2025	5	1896	6 804,50	15	8501	30 669,57
15/08/2025	24	11606	41 566,66	15	7501	27 138,62
18/08/2025	4	4001	15 183,63	47	32001	122 451,51
19/08/2025	38	13206	51 197,02	5	3206	12 757,09
20/08/2025	19	11001	41 623,93	7	5149	19 489,38
21/08/2025	7	2001	7 423,71	4	1853	6 910,19
22/08/2025	8	5001	18 859,77	24	8001	30 219,78
25/08/2025	15	13133	48 480,21	2	1001	3 663,79
26/08/2025	33	17869	63 697,45	5	3001	10 739,65
27/08/2025	14	6013	21 145,86	8	3513	12 416,35
28/08/2025	28	9001	31 503,50	12	6501	23 007,56
29/08/2025	21	7021	24 353,32	24	4275	14 882,51

PRESS RELEASE

01/09/2025	9	6001	20 814,47	14	13227	46 340,66
02/09/2025	12	5481	18 783,61	17	16001	53 925,93
03/09/2025	7	2211	7 430,66	9	6211	21 021,07
04/09/2025	3	1052	3 615,52	16	12052	41 134,32
05/09/2025	5	4501	15 420,38	9	8001	27 552,40
08/09/2025	12	4501	15 459,45	4	4501	15 555,46
09/09/2025	6	3001	10 290,46	14	13501	47 037,48
10/09/2025	23	12764	45 075,17	25	11264	40 103,11
11/09/2025	22	4501	16 198,56	14	7001	25 134,57
12/09/2025	7	4001	14 397,64	12	4001	14 513,63
15/09/2025	7	4001	14 605,61	8	4001	14 669,59
16/09/2025	12	5001	18 184,09	6	6001	21 965,64
17/09/2025	10	3001	10 705,62	5	2001	7 159,62
18/09/2025	22	5001	18 081,57	16	9001	32 703,60
19/09/2025	23	11001	40 028,68	19	10001	36 840,68
22/09/2025	20	15749	51 836,26	13	8554	28 186,71
23/09/2025	62	44001	140 309,95	16	8196	27 296,78
24/09/2025	28	17331	53 707,56	14	12331	38 515,26
25/09/2025	22	20060	61 994,43	13	13441	41 859,44
26/09/2025	12	4793	14 835,25	25	11293	35 071,65
29/09/2025	6	3001	9 453,15	16	6443	20 459,10
30/09/2025	3	2001	6 423,17	16	9210	29 737,52
01/10/2025	5	4001	13 123,28	17	15969	53 358,66
02/10/2025	3	1001	3 443,43	17	14001	48 503,38
03/10/2025	31	9501	33 034,50	17	9001	31 645,54

PRESS RELEASE

06/10/2025	31	14002	47 928,85	29	19001	65 768,54
07/10/2025	13	5162	17 539,96	8	5001	17 051,41
08/10/2025	21	8001	27 452,39	16	13163	45 594,92
09/10/2025	1	1	3,48	46	27001	100 285,49
10/10/2025	45	14001	52 814,85	5	2001	7 653,54
13/10/2025	33	12606	46 241,96	27	10006	37 004,09
14/10/2025	41	20401	73 853,86	34	17061	62 115,69
15/10/2025	7	5432	19 588,01	23	15329	55 808,60
16/10/2025	11	6001	21 745,40	16	6001	21 920,51
17/10/2025	22	16006	58 044,96	28	22049	80 967,90
20/10/2025	38	32773	117 558,06	28	25273	91 040,93
21/10/2025	17	12102	43 176,79	36	19602	71 114,68
22/10/2025	17	9001	33 797,76	12	9001	33 988,59
23/10/2025	35	14941	55 110,18	16	10001	36 845,78
24/10/2025	18	9001	33 039,34	16	11001	40 629,66
27/10/2025	32	15436	56 785,34	20	11376	42 074,36
28/10/2025	52	21001	75 643,71	7	6001	22 019,65
29/10/2025	18	6001	21 953,46	14	9001	32 921,61
30/10/2025	13	11107	40 074,39	14	10522	38 164,77
31/10/2025	39	12662	45 997,50	19	14377	52 364,20
03/11/2025	37	19000	67 860,40	8	8026	28 752,26
04/11/2025	52	16564	58 705,47	24	20128	71 784,70
05/11/2025	46	27614	97 857,94	26	18879	67 282,49
06/11/2025	15	10296	36 012,53	7	10296	36 214,53
07/11/2025	56	15944	54 959,77	9	5959	20 535,91

PRESS RELEASE

10/11/2025	6	3205	11 534,19	48	35205	125 685,72
11/11/2025	12	9001	32 451,67	22	13001	47 171,66
12/11/2025	4	2001	7 381,67	14	14001	52 377,60
13/11/2025	21	9255	34 669,69	8	6255	23 579,29
14/11/2025	22	6163	22 760,27	27	11909	44 095,45
17/11/2025	12	8001	30 017,75	32	9264	34 961,32
18/11/2025	13	10010	37 086,75	6	4001	15 043,76
19/11/2025	17	9001	34 098,13	20	14001	53 681,79
20/11/2025	29	16001	60 091,60	1	1	3,89
21/11/2025	11	5001	18 405,68	11	5001	18 469,69
24/11/2025	6	3065	11 486,21	11	6279	23 704,23
25/11/2025	22	20545	77 477,25	54	33835	128 769,24
26/11/2025	14	5255	20 689,20	46	14751	58 720,19
27/11/2025	2	1001	4 070,00	23	14001	58 208,04
28/11/2025	10	4324	19 125,40	8	4324	18 952,26
01/12/2025	12	8001	35 140,47	22	9001	39 816,46
02/12/2025	12	7296	33 604,87	31	13296	61 688,52
03/12/2025	18	14081	69 103,07	17	12081	59 322,66
04/12/2025	54	37001	179 047,10	25	17001	82 822,92
05/12/2025	54	36751	170 003,14	40	26501	123 631,67
08/12/2025	26	9002	41 426,30	27	12252	57 036,74
09/12/2025	26	9341	43 247,43	30	11751	54 857,90
10/12/2025	21	6429	30 110,03	29	18519	88 762,12
11/12/2025	25	16351	81 534,92	50	31851	160 968,90
12/12/2025	19	12001	60 598,21	38	9001	45 865,14

PRESS RELEASE

15/12/2025	18	11001	55 134,15	3	2001	10 005,10
16/12/2025	18	12560	62 060,09	29	12560	62 553,57
17/12/2025	18	9967	49 426,95	17	7967	39 690,80
18/12/2025	11	4001	19 770,94	11	7001	34 917,70
19/12/2025	24	10001	49 369,04	21	10001	49 554,96
22/12/2025	12	9001	44 631,01	28	14001	70 116,03
23/12/2025	15	9797	49 758,38	37	13797	70 461,42
24/12/2025	10	7067	36 063,04	13	6067	31 065,65
29/12/2025	14	8500	43 934,89	22	15001	77 925,09
30/12/2025	5	2001	10 642,80	14	3665	19 561,90
31/12/2025	14	7001	36 965,28	7	2659	14 036,14